Search

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

Dec 13 2012 Posted in Press releases

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

“Nothing about us without us”: how patient advocacy is changing the game

Aug 19 2019

Nuno Borges MBBS MRes, on behalf of YoungEHA
When it comes to advancing medical care, there is no denying that patients are at the core of everything we do.

EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Syndromes

Nov 14 2019 Posted in Meeting reports

The second scientific meeting on EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Disorders and Leukemia Predisposing Genes was held on October 10-12, 2019 in Prague, Czech Republic.

EHA-EMN Joint Session at the European Myeloma Network Meeting EMN2023

Apr 26 2023

On Saturday, 22 April, EHA and EMN brought together patients, regulators and clinicians to discuss Novel Endpoints in Multiple Myeloma.

The EHA Guidelines Workshop, a meaningful and successful first Series!

May 19 2021 Posted in Meeting reports

November 2020 – April 2021

In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.

Policy & advocacy

At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.